SCHEMBL2643554

SCHEMBL2643554

O=C1c2c(F)cccc2C(CCO)N1Cc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.38
HCRTR2 O43614 5/20 0.37
HCRTR1 O43613 3/20 0.37
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CASP3 P42574 1/20 0.35
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
UBE2N P61088 1/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2645157 0.87 MAPT (0.41) MAPTALDH1A1RXFP1LMNA
SCHEMBL2643582 0.82 MAPT (0.40) MAPTHCRTR2HCRTR1ALDH1A1MEN1
SCHEMBL2644233 0.76 MAPT (0.40) MAPTRXFP1
SCHEMBL2644694 0.76 MAPT (0.39) MAPTHCRTR2HCRTR1ALDH1A1MEN1
SCHEMBL2643902 0.75 MAPT (0.50) MAPTALDH1A1MEN1KMT2ACASP3
SCHEMBL2643302 0.75 MAPT (0.38) MAPTALDH1A1LMNAL3MBTL1
SCHEMBL2643060 0.75 KCNH2 (0.40) MAPTALDH1A1KMT2A
SCHEMBL2644952 0.74 MAPT (0.36) MAPTHCRTR2HCRTR1KMT2AHTR2C
SCHEMBL2669439 0.73 CHRM3 (0.35) MAPTLMNA
SCHEMBL9071627 0.73 MAPT (0.37) MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8796313-B2 Substituted dihydroisoindolones as allosteric modulators of glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2014-08-05 US disclosed
EP-1960385-A1 SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-27 EP disclosed
WO-2007053503-A1 SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099930-A1 Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase GCK, GCKR, GPR119 MAPT 3322/4885HCRTR2 4122/4885HCRTR1 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.